TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05952115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbar motor control exercises
Description: the patients will receive lumbar motor control exercises in the form of three exercises (Abdominal draw in maneuver, side-bridge, and quadruped) and the level of difficulty increased each week. For all exercises, the number of repetitions stayed the same, but the difficulty increased each week, and we progressed to the advanced level of each of the three exercises.~This training achieves co-contraction of the local/deep stabilizing muscles (Transversus abdominis and multifidus) and strengthening the global/large spinal stabilizers (erector spinae and obliques).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical stabilization exercises
Description: The exercise program consisted of an axial elongation exercise, cranio-cervical flexion exercise, cervical extension exercise, and cervical-scapulothoracic strengthening exercise. The exercise program progressed based on the exercise tolerance of the patients by increasing the repetition of the exercise (10 reps to 15 reps to 20 reps). And for the resistive exercise, the participants change to an elastic band with greater resistance (progress to the next color resistance band). Exercises were performed for 20 min/session, and an exercise log recording the date and repetition of the exercises was maintained by the therapist for each participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical stabilization exercises
Description: The exercise program consisted of an axial elongation exercise, cranio-cervical flexion exercise, cervical extension exercise, and cervical-scapulothoracic strengthening exercise. The exercise program progressed based on the exercise tolerance of the patients by increasing the repetition of the exercise (10 reps to 15 reps to 20 reps). And for the resistive exercise, the participants change to an elastic band with greater resistance (progress to the next color resistance band). Exercises were performed for 20 min/session, and an exercise log recording the date and repetition of the exercises was maintained by the therapist for each participant.
Study: NCT05528887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CAR-T cells
Description: D0: CAR-T cells will be infused intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: D-5 to D-3: Fludarabine (30 mg/m\^2/day) will be administered intravenously for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: D-5 to D-3: Cyclophosphamide (500 mg/m\^2/day) will be administered intravenously for 3 days.
Study: NCT06173492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental extraction
Description: After local anesthesia (mepivacaine 2%), the tooth is extracted atraumatically with levers and forceps taking care to preserve the cortex. The roots of multi-rooted teeth are separated before extraction. The pocket epithelium and granulation tissue inside the socket are removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental extraction
Description: After local anesthesia (mepivacaine 2%), the tooth is extracted atraumatically with levers and forceps taking care to preserve the cortex. The roots of multi-rooted teeth are separated before extraction. The pocket epithelium and granulation tissue inside the socket are removed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: The clot obtained by centrifugation is made into PRF cylinders and inserted into the socket and compacted.
Study: NCT05804864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM501
Description: 1a: The program evaluated six dose levels, i.e., 0.1, 0.3, 0.6, 1.2, 1.8, 2.4 mg/kg, An accelerated titration was performed in the 0.1 and 0.3 mg/kg dose groups, and then a Bayesian optimal interval design was used to determine MTDS for four subsequent dose levels. Ib: The antitumor activity of KM501 monotherapy in subjects with specific types of tumors that are HER2-positive or express, amplify, or mutate will be evaluated at the RP2D dose level
Study: NCT04346394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine HCl
Description: Yohimbine hydrochloride will be used to manipulate the noradrenergic system during some of the assessments. By measuring the amounts of hormones the body produces before and after yohimbine hydrochloride administration, researchers can assess how well the noradrenergic system is functioning
Study: NCT05237882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders
Description: The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
Study: NCT05405543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-224
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-224
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-224
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-224
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05127200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Starstim (Neuroelectrics)
Description: Anodal transcutaneous spinal direct current stimulation (a-tsDCS)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Starstim (Neuroelectrics)
Description: Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
Study: NCT04884074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Sleeve Gastrectomy plus Anterior Crural Repair
Description: The procedure is performed in a similar fashion as standard sleeve gastrectomy. After gastric mobilization is completed as standard sleeve gastrectomy, the anterior phrenoesophageal ligament is divided and distal 3cm esophagus is mobilized. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist and the hiatus opening is closed with 2/0 non-absorbable suture over the bougie anterior to the esophagus. The hiatus repair was sized by comfortably placement a dissection forceps adjacent to the esophagus without tension. Sleeve gastrectomy is then performed as the standard technique.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard sleeve gastrectomy (SSG, the control group)
Description: The procedure is performed in French position with a standard 5-port approach and a pneumoperitoneum not exceeding 15mmHg.~The greater omentum is then completely detached from the greater curvature of stomach using either ultrasonic or bipolar shear device. All adhesion between posterior gastric wall and pancreatic capsule is freed and the cardia is completely free with left crura completely exposed. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist with its balloon tip reaching the gastric antrum and insufflated with 50cc of air. Sleeve gastrectomy is then performed using laparoscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up cardia at about 1cm lateral to the angle of His, along the Mid-sleeve tube which is lying against the lesser curve of stomach. The staple line is reinforced with absorbable sutures. Distal stomach is anchored at retroperitoneum with non-absorbable stitch.
Study: NCT06494371

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-HL30 cells
Description: Prior to infusion of the LCAR-HL30, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
Study: NCT04794478

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom Continuous Glucose Monitoring System
Description: Dexcom Continuous Glucose Monitoring System
Study: NCT04586231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Immediate-release 40 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Capsule available in 4 mg and 10 mg dosages

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Tablet available in 20 mg, 40 mg and 60 mg dosages
Study: NCT06496971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: An anti-angiogenic agent to block tumor growth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: An anti-angiogenic agent to block tumor growth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microbubble
Description: Open the Blood-Brain Barrier (BBB) using focused ultrasound and microbubble

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Focused Ultrasound
Description: Open the Blood-Brain Barrier (BBB) using focused ultrasound and microbubble
Study: NCT04419389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 (eprenetapopt) + Acalabrutinib in CLL
Description: APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL
Description: APR-246 D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT
Description: APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule Venetoclax and Rituxiab will be given at a standard dose and schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT
Description: APR-246 4.5 g/d D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule
Study: NCT06362200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 40 Hz tACS intervention
Description: The central electrode is placed in the CP6 and the other four electrodes are placed around the CP6. 40 Hz tACS group participants will receive alternating current stimulation (40Hz, 2.0mA, 20min/time, three times a day, 40 times in total) for 1 week. Subjects in the placebo comparator group will receive sham tACS for 1 week, which mimics the tACS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 40 Hz tACS intervention
Description: The central electrode is placed in the CP6 and the other four electrodes are placed around the CP6. 40 Hz tACS group participants will receive alternating current stimulation (40Hz, 2.0mA, 20min/time, three times a day, 40 times in total) for 1 week. Subjects in the placebo comparator group will receive sham tACS for 1 week, which mimics the tACS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs.
Study: NCT04005989

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stromal Cells Injection
Description: Adipose stromal cell

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stromal Cells Injection
Description: Adipose stromal cell

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stromal Cells Injection
Description: Adipose stromal cell

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Stromal Cells Injection
Description: Adipose stromal cell
Study: NCT04910373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Extensively Hydrolyzed Formula
Description: experimental powder formula

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Extensively Hydrolyzed Formula
Description: placebo powder formula
Study: NCT06427915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OLIPOP prebiotic soda
Description: 12oz serving containing Carbonated Water, OLISMART(TM) (Cassava Root Fiber, Acacia Fiber, Guar Fiber, Nopal Cactus\*, Marshmallow Root\*, Calendula Flower\*, Kudzu Root\*), Cassava Root Syrup, Apple Juice Concentrate, Lime Juice, Natural Cola Flavor, Alpinia Galanga Root\*, Stevia Leaf\*, Himalayan Pink Salt, Green Tea Caffeine\*, Natural Caramel Flavor, Natural Vanilla Flavor, Cinnamon\* (\*Extract)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OLIPOP prebiotic soda
Description: 12oz serving containing Carbonated Water, OLISMART(TM) (Cassava Root Fiber, Acacia Fiber, Guar Fiber, Nopal Cactus\*, Marshmallow Root\*, Calendula Flower\*, Kudzu Root\*), Cassava Root Syrup, Apple Juice Concentrate, Lime Juice, Natural Cola Flavor, Alpinia Galanga Root\*, Stevia Leaf\*, Himalayan Pink Salt, Green Tea Caffeine\*, Natural Caramel Flavor, Natural Vanilla Flavor, Cinnamon\* (\*Extract)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional sugar-sweetened cola
Description: 12oz serving containing carbonated water, high fructose corn syrup, caramel color, phosphoric acid, natural flavors, caffeine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional sugar-sweetened cola
Description: 12oz serving containing carbonated water, high fructose corn syrup, caramel color, phosphoric acid, natural flavors, caffeine
Study: NCT05408468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAMCOPE-ICU
Description: (1) FAMCOPE-ICU is a digital eHealth emotion regulation and coping intervention. FAMCOPE-ICU contains three digital modules representing the three interventional doses. Corresponding with Gross's Extended Process Model of Emotion Regulation, the three respective doses entail assessments, adaptive feedback, and interactive activities pertaining to understanding their affective experiences, learning strategies to regulate emotions and stress, and practicing these skills in a virtual decision-making task. Each dose of the intervention is expected to last 10-15 minutes
Study: NCT04145479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: exercise
Study: NCT06479993

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chlorella supplementation
Description: Supplementation with chlorella (6g/day for 3-weeks)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Supplementation with placebo - microcrystalline cellulose (6g/day for 3-weeks)
Study: NCT04298151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconomer Improved
Description: glass ionomer restoration reinforced with nano-zirconia particles to improve strength and esthetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketac Molar quick Aplicap
Description: highly viscous glass ionomer with improved mechanical properties than the conventional GI
Study: NCT05832957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drive fun
Description: The Drive Fun intervention program aims to promote the development of adaptive self-awareness and facilitate the acquisition of management strategies that foster safe and confident driving among participants. The program utilizes a driving simulator to provide a guided learning experience, which incorporates various sources of information, as well as games and thinking tasks. Additionally, participants will engage in reflective exercises that draw upon their occupational experiences and their driving performance within the simulator. Parental involvement is also incorporated to ensure ongoing support for the continued practice of learned skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: 7 individual sessions of one hour at the driving lab at Tel Aviv university and 4 group sessions- 90 minutes by Zoom of group sessions of an educational intervention of safe driving according to Ministry of Education. The intervention focuses only on the cognitive aspects since it is based on imparting educational knowledge regarding safe driving with opportunities for gamified, non-driving-related activities such as board games (e.g., rush hour) and social games

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: one-time short guidance on safe driving at the end of the study.
Study: NCT05796843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 360 Degrees virtual reality-based mirror therapy
Description: Participants will receive mirror therapy using a virtual reality device (Pico G2 VR 4K, Pico, China). They will be asked to follow tasks that are played in HMD using their paralyzed hand. The video played using HMD will be video taped using 360 degree camera prior to the treatment. The 360MT will last 30 minutes/session, 3 sessions a week for 4 weeks. The tasks are finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional mirror therapy
Description: Participants will receive mirror therapy using an acrylic mirror (40cm x 40cm x 3cm) that reflects unparalyzed side of them. They will be asked to perform tasks including finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions. They will be asked to follow the reflection on mirror using their paralyzed limb. The TMT will last 30 minutes/session, 3 sessions a week for 4 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: Participants will receive conventional physical therapy including neurodevelopmental therapy, muscle strengthening exercises, and joint mobilization which will be provided 60 minutes per day, 5 sessions a week, for 4 weeks. The therapy will follow upper extremity rehabilitation protocol which consists of three phases of warm up, circuit, and cool down exercises

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Participants will receive conventional physical therapy including neurodevelopmental therapy, muscle strengthening exercises, and joint mobilization which will be provided 60 minutes per day, 5 sessions a week, for 4 weeks. The therapy will follow upper extremity rehabilitation protocol which consists of three phases of warm up, circuit, and cool down exercises

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Participants will receive conventional physical therapy including neurodevelopmental therapy, muscle strengthening exercises, and joint mobilization which will be provided 60 minutes per day, 5 sessions a week, for 4 weeks. The therapy will follow upper extremity rehabilitation protocol which consists of three phases of warm up, circuit, and cool down exercises
Study: NCT06492252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: To assess functional connectivity patterns between regions that predict learning.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: To assess functional connectivity patterns between regions that predict learning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory baseline in speech
Study: NCT05588492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycin-containing regimen
Description: Rifamycin-containing regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycin-free regimen
Description: Rifamycin-free regimen
Study: NCT05958303

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant Cocktail
Description: Total dosing of 1000 mg vitamin C, 600 IU vitamin E, and 600 mg of alpha lipoic acid.
Study: NCT06025058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easy Dew MD Regen Cream
Description: The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Easy Dew MD Regen Cream
Description: The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
Study: NCT05958303

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04713020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention:APP educational programs
Description: Use mobile device education programs to improve disease knowledge and self-efficacy of stroke patients, and reduce depression

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention:general care
Description: general care
Study: NCT06446739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Renal Replacement Therapy (CRRT)
Description: Continuous Renal Replacement Therapy (CRRT) is a continuous form of acute renal replacement (hemofiltration/dialysis) therapy provided to critically ill patients with multi-organ dysfunction receiving life support in the intensive care unit (ICU).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Renal Replacement Therapy (CRRT)
Description: Continuous Renal Replacement Therapy (CRRT) is a continuous form of acute renal replacement (hemofiltration/dialysis) therapy provided to critically ill patients with multi-organ dysfunction receiving life support in the intensive care unit (ICU).